---
title: Anxiolytic Drugs
type: content
phase: 1
status: complete
priority: high
tags: [anxiolytics, benzodiazepines, buspirone, GABA, anxiety, dependence, sedation]
created: 2025-11-08
last_modified: 2025-11-08
---

# Anxiolytic Drugs

## Introduction

Anxiolytic drugs, also known as anti-anxiety agents or sedatives, are medications used to treat anxiety disorders and related conditions. The two main classes are benzodiazepines (most commonly prescribed) and buspirone (non-benzodiazepine anxiolytic). Understanding their mechanisms, therapeutic uses, and risks (particularly dependence and withdrawal) is essential for safe prescribing.

## Classification

### Major Classes

1. **Benzodiazepines**
   - Most commonly prescribed anxiolytics
   - GABA-A receptor positive allosteric modulators
   - Rapid onset, high efficacy
   - Risk: Dependence, tolerance, withdrawal

2. **Buspirone**
   - Non-benzodiazepine anxiolytic
   - 5-HT1A partial agonist
   - Slow onset, no dependence
   - Effective for generalized anxiety disorder

3. **Other Agents**
   - SSRIs/SNRIs (first-line for most anxiety disorders)
   - Hydroxyzine (antihistamine)
   - Gabapentin, pregabalin
   - Beta-blockers (performance anxiety)

---

## Benzodiazepines

### Mechanism of Action

**Target**: GABA-A receptor (ligand-gated chloride channel)

**GABA-A Receptor Structure**:
- Pentameric (5 subunits): 2α, 2β, 1γ
- GABA binding sites: Between α and β subunits
- **Benzodiazepine binding site**: Between α and γ subunits

**Mechanism**:
1. Benzodiazepines bind to BZD site (allosteric site)
2. **Positive allosteric modulation**: ↑affinity of GABA for receptor
3. ↑Frequency of chloride channel opening (NOT duration - barbiturates ↑duration)
4. ↑Chloride influx → hyperpolarization
5. ↓Neuronal excitability

**Key Distinction**:
- **Benzodiazepines**: Require GABA present (allosteric modulators) → **ceiling effect** → safer
- **Barbiturates**: Direct GABA-A agonists (can open channel without GABA) → **no ceiling effect** → dangerous

**Effects**:
- **Anxiolytic** (anti-anxiety)
- **Sedative-hypnotic** (sleep-inducing)
- **Muscle relaxant** (spinal cord)
- **Anticonvulsant**
- **Amnestic** (anterograde amnesia)

### Pharmacokinetics

**Absorption**:
- Oral: Rapid absorption (lipophilic)
- IM: Variable absorption (diazepam poorly absorbed IM)
- IV: Immediate onset
- Sublingual: Faster than oral for some (alprazolam)

**Distribution**:
- Highly lipophilic → extensive distribution
- Rapid CNS penetration
- High protein binding (albumin)

**Metabolism**:
- Hepatic metabolism (CYP3A4, CYP2C19 primarily)
- **Phase I** (oxidation): → active metabolites
- **Phase II** (glucuronidation): → inactive metabolites

**Active Metabolites** (important for duration):
- **Diazepam** → desmethyldiazepam (t½ 100 hours!)
- **Chlordiazepoxide** → desmethylchlordiazepoxide, demoxepam
- **Clorazepate, prazepam** → desmethyldiazepam
- **Alprazolam, triazolam**: No active metabolites

**Classification by Half-Life**:

**Ultra-Short Acting** (t½ <6 hours):
- Midazolam (2-6 hours)
- Triazolam (2-3 hours)

**Short-Intermediate Acting** (t½ 6-24 hours):
- Alprazolam (12 hours)
- Lorazepam (12-18 hours)
- Oxazepam (8-12 hours)
- Temazepam (10-20 hours)

**Long Acting** (t½ >24 hours):
- Diazepam (20-100 hours with metabolites)
- Chlordiazepoxide (10-30 hours, metabolites 100+ hours)
- Clonazepam (18-50 hours)
- Flurazepam (metabolite: 100 hours)

### Individual Benzodiazepines

#### Diazepam (Valium)

**Pharmacokinetics**:
- Oral, IV, rectal
- **Long half-life**: 20-100 hours (with active metabolites)
- Active metabolite: Desmethyldiazepam (t½ 100 hours)
- CYP3A4, CYP2C19 metabolism

**Clinical Uses**:
1. **Generalized anxiety disorder (GAD)** (short-term)
2. **Alcohol withdrawal** (long-acting preferred for smooth taper)
3. **Muscle spasms**, spasticity
4. **Status epilepticus** (IV, rectal gel)
5. **Procedural sedation**
6. **Panic disorder** (less preferred than alprazolam)

**Advantages**:
- Long half-life → smooth effect, less rebound anxiety
- Good for alcohol withdrawal (auto-tapering effect)
- IV and rectal formulations
- Multiple indications

**Disadvantages**:
- Long half-life → accumulation, hangover effect (especially elderly)
- Active metabolites → prolonged effects
- IM absorption poor

**Dosing**:
- Anxiety: 2-10 mg BID-QID
- Alcohol withdrawal: 10-20 mg q6h PRN (symptom-triggered or fixed-schedule)
- Status epilepticus: 5-10 mg IV q10-15min (max 30 mg)

#### Lorazepam (Ativan)

**Pharmacokinetics**:
- Oral, IV, IM, SL
- **Intermediate half-life**: 12-18 hours
- **No active metabolites** (direct glucuronidation - Phase II only)
- **Good IM absorption** (unlike diazepam)

**Clinical Uses**:
1. **Generalized anxiety disorder**
2. **Panic disorder**
3. **Alcohol withdrawal**
4. **Status epilepticus** (IV)
5. **Acute agitation** (IM/IV)
6. **Procedural sedation**
7. **Chemotherapy-induced nausea** (adjunct)
8. **Insomnia** (short-term)

**Advantages**:
- **Preferred in elderly and liver disease** (no active metabolites, glucuronidation preserved)
- **Good IM absorption**
- Intermediate duration (not too short, not too long)
- Reliable pharmacokinetics
- IV formulation for emergencies

**Disadvantages**:
- More sedating than some others
- Can accumulate with repeated dosing

**Dosing**:
- Anxiety: 0.5-2 mg BID-TID
- Agitation: 1-2 mg IM/IV
- Status epilepticus: 4 mg IV, repeat q10min (max 8 mg)

**Clinical Pearl**: **Drug of choice for elderly and liver disease**

#### Alprazolam (Xanax)

**Pharmacokinetics**:
- Oral (IR, XR)
- **Intermediate half-life**: 12 hours
- No active metabolites
- CYP3A4 metabolism

**Clinical Uses**:
1. **Panic disorder** (FDA-approved, highly effective)
2. **Generalized anxiety disorder**
3. **Social anxiety disorder** (off-label)

**Advantages**:
- **Highly effective for panic disorder**
- Rapid onset (15-30 minutes)
- Anxiolytic at lower doses than sedative
- XR formulation available (once-daily)

**Disadvantages**:
- **High abuse potential** (euphoric effect, rapid onset)
- **Severe withdrawal** (more than other benzodiazepines)
- **Interdose rebound anxiety** (short half-life)
- **Difficult to discontinue** (physical dependence)
- Many drug interactions (CYP3A4)

**Dosing**:
- Panic disorder: 1-6 mg/day (divided TID-QID or XR once daily)
- GAD: 0.5-4 mg/day (divided)

**Clinical Pearls**:
- **Most commonly prescribed benzodiazepine** in US
- **Highest abuse potential**
- **Hardest to discontinue**
- **Requires slow taper** (reduce by 0.25 mg every 1-2 weeks)

#### Clonazepam (Klonopin)

**Pharmacokinetics**:
- Oral
- **Long half-life**: 18-50 hours
- No active metabolites
- CYP3A4 metabolism

**Clinical Uses**:
1. **Panic disorder** (FDA-approved)
2. **Social anxiety disorder** (off-label, effective)
3. **Seizure disorders** (absence, myoclonic)
4. **Acute mania** (adjunct)
5. **REM sleep behavior disorder**
6. **Restless legs syndrome**

**Advantages**:
- Long half-life → less rebound anxiety than alprazolam
- BID dosing (sometimes once daily)
- Less abuse potential than alprazolam (slower onset)
- Multiple uses (anxiety, seizures)

**Disadvantages**:
- Long half-life → sedation, accumulation
- Dependence and withdrawal (though less severe than alprazolam)

**Dosing**:
- Panic disorder: 0.5-2 mg/day (divided BID)
- Seizures: 1.5-20 mg/day

**Clinical Pearl**: **Preferred over alprazolam for panic disorder** (longer duration, less rebound)

#### Temazepam (Restoril)

**Pharmacokinetics**:
- Oral
- Intermediate half-life: 10-20 hours
- No active metabolites (direct glucuronidation)

**Clinical Uses**:
1. **Insomnia** (short-term)

**Advantages**:
- Good for sleep onset and maintenance
- No active metabolites

**Dosing**: 7.5-30 mg qhs

#### Triazolam (Halcion)

**Pharmacokinetics**:
- Oral
- **Ultra-short half-life**: 2-3 hours
- No active metabolites
- CYP3A4 metabolism

**Clinical Uses**:
1. **Insomnia** (sleep onset only)
2. **Jet lag**

**Advantages**:
- Very short duration → no morning hangover

**Disadvantages**:
- **Anterograde amnesia** (common)
- Rebound insomnia
- Early morning awakening (short duration)
- Not good for sleep maintenance

**Dosing**: 0.125-0.25 mg qhs

**Clinical Pearl**: **Highest risk of anterograde amnesia** among benzodiazepines

#### Midazolam (Versed)

**Pharmacokinetics**:
- IV, IM (oral liquid for pediatrics)
- **Ultra-short half-life**: 2-6 hours
- **Most lipophilic** → fastest CNS penetration
- CYP3A4 metabolism

**Clinical Uses**:
1. **Procedural sedation** (IV/IM)
2. **Anesthesia induction**
3. **Status epilepticus** (refractory)
4. **Sedation in ICU** (continuous infusion)

**Advantages**:
- **Fastest onset** (1-5 minutes IV)
- **Shortest duration**
- Excellent for procedures

**Disadvantages**:
- **Respiratory depression** (especially with opioids)
- **Anterograde amnesia** (desired for procedures)
- Parenteral only (for adults)

**Dosing**:
- Procedural sedation: 1-5 mg IV (titrate slowly)
- Continuous infusion: 0.02-0.1 mg/kg/h

**Reversal Agent**: **Flumazenil** (see below)

#### Chlordiazepoxide (Librium)

**Pharmacokinetics**:
- Oral
- Long half-life with metabolites (100+ hours)

**Clinical Uses**:
1. **Alcohol withdrawal** (historical - first benzodiazepine used)
2. Anxiety (less commonly used now)

**Dosing**: 25-100 mg TID-QID (alcohol withdrawal)

#### Oxazepam (Serax)

**Pharmacokinetics**:
- Oral
- Intermediate half-life: 8-12 hours
- **No active metabolites** (direct glucuronidation)
- **Slower onset** than diazepam

**Clinical Uses**:
1. Anxiety
2. **Alcohol withdrawal** (preferred in liver disease)

**Advantages**:
- **Safe in liver disease** (glucuronidation preserved, no active metabolites)
- **Safe in elderly**
- Lower abuse potential (slower onset)

**Dosing**: 10-30 mg TID-QID

**Clinical Pearl**: **Preferred in liver disease** (with lorazepam)

#### Clorazepate (Tranxene)

**Pharmacokinetics**:
- Oral
- **Prodrug** → rapidly converted to desmethyldiazepam in stomach
- Long half-life (metabolite)

**Clinical Uses**:
1. Anxiety
2. **Alcohol withdrawal**
3. **Partial seizures** (adjunct)

**Dosing**: 15-60 mg/day

### Benzodiazepine Adverse Effects

**Common**:

1. **Sedation, drowsiness**:
   - Most common
   - Dose-dependent
   - Tolerance develops

2. **Cognitive impairment**:
   - Memory impairment (anterograde amnesia)
   - Impaired attention, concentration
   - Psychomotor slowing

3. **Psychomotor impairment**:
   - Ataxia, incoordination
   - **Fall risk** (especially elderly)
   - **Driving impairment**

4. **Respiratory depression**:
   - Dose-dependent
   - **Synergistic with opioids, alcohol, barbiturates**
   - Can be fatal in overdose (especially with other CNS depressants)

5. **Paradoxical reactions** (rare, 1-2%):
   - Agitation, aggression, disinhibition
   - More common in children, elderly
   - Consider discontinuation

**Long-Term Effects**:

6. **Tolerance**:
   - Develops to sedative effects (days to weeks)
   - Develops to anxiolytic effects (slower, months)
   - Less tolerance to amnestic effects

7. **Physical dependence**:
   - Develops with regular use (weeks to months)
   - Faster with short-acting agents (alprazolam, triazolam)
   - See withdrawal syndrome below

8. **Psychological dependence**:
   - Abuse potential (especially alprazolam, diazepam)
   - Risk factors: History of substance abuse

9. **Cognitive decline**:
   - Controversial - possible association with dementia (chronic use)

**Special Populations**:

**Elderly**:
- ↑Sensitivity to benzodiazepines
- ↑Risk of falls, fractures
- ↑Risk of cognitive impairment, delirium
- **Beers Criteria**: Avoid in elderly if possible
- If necessary: Use low doses, shorter-acting agents (lorazepam, oxazepam)

**Pregnancy**:
- Category D
- Risk: Cleft lip/palate (controversial)
- Neonatal withdrawal ("floppy baby syndrome")
- Avoid in first trimester if possible

**Respiratory Disease**:
- Caution in COPD, sleep apnea (respiratory depression)

### Benzodiazepine Withdrawal Syndrome

**Definition**: Symptoms following abrupt discontinuation or dose reduction

**Risk Factors**:
- **Duration of use**: >4 weeks (especially >6 months)
- **Dose**: Higher doses
- **Half-life**: Short-acting > long-acting
- **Specific agent**: Alprazolam, triazolam > others
- **Rate of taper**: Abrupt > gradual

**Clinical Features**:

**Mild-Moderate** (common):
- **Anxiety** (rebound, may exceed baseline)
- **Insomnia** (rebound)
- Irritability, agitation
- Tremor
- Sweating, palpitations
- Headache
- Muscle tension, aches
- GI upset (nausea, vomiting, diarrhea)
- **Perceptual disturbances** (hypersensitivity to light, sound, touch)

**Severe** (less common, but serious):
- **Seizures** (3-4 days after stopping, can occur up to 2 weeks)
  - Grand mal seizures
  - Risk highest with short-acting, high-dose, abrupt cessation
- Confusion, delirium
- Psychosis (rare)
- Severe autonomic symptoms (hypertension, tachycardia)

**Time Course**:
- **Short-acting** (alprazolam, triazolam): Onset 1-2 days, peak 2-4 days
- **Long-acting** (diazepam, clonazepam): Onset 2-7 days, peak 7-14 days

**Duration**: Days to weeks (sometimes months - protracted withdrawal)

**Protracted Withdrawal Syndrome** (10-25%):
- Anxiety, insomnia, dysphoria persist months
- Mechanism: Slow GABA-A receptor upregulation

**Treatment**:

1. **Prevention**: Gradual taper (see below)
2. **Acute withdrawal**:
   - **Reinstate benzodiazepine** at previous dose
   - Then **slow taper**
3. **Symptomatic treatment**:
   - β-blockers (propranolol) for autonomic symptoms
   - Carbamazepine (may prevent seizures)
   - Supportive care
4. **Severe withdrawal**:
   - Hospitalization
   - Long-acting benzodiazepine (diazepam) IV/oral
   - Seizure precautions

**Clinical Pearl**: **Benzodiazepine withdrawal can be life-threatening** (seizures) - never stop abruptly after chronic use

### Benzodiazepine Tapering

**Indications for Taper**:
- All patients on chronic benzodiazepines (>4 weeks)
- Goal: Prevent withdrawal syndrome

**Principles**:

1. **Switch to long-acting agent** (optional but helpful):
   - Convert short-acting (alprazolam, triazolam) to long-acting (clonazepam, diazepam)
   - **Clonazepam equivalent**: Alprazolam 0.5 mg = Clonazepam 0.25 mg
   - **Diazepam equivalent**: See conversion table below

2. **Slow, gradual taper**:
   - **Rate**: 10-25% dose reduction every 1-2 weeks
   - **Slower for**: Long-term use, high doses, alprazolam
   - **Total duration**: Weeks to months (sometimes 6-12 months)

3. **Monitor for withdrawal symptoms**:
   - If symptoms occur: Hold taper, consider slower rate

4. **Supportive measures**:
   - Psychological support, CBT
   - Treat underlying anxiety disorder (SSRIs)
   - Avoid other CNS depressants

**Benzodiazepine Equivalency (Approximate)**:
- Alprazolam 0.5 mg
- Clonazepam 0.25 mg
- Lorazepam 1 mg
- Diazepam 5 mg
- Chlordiazepoxide 10 mg
- Temazepam 15 mg
- Triazolam 0.25 mg

**Example Taper** (Alprazolam 2 mg/day → discontinuation):
1. **Switch to clonazepam**: Alprazolam 2 mg = Clonazepam 1 mg
2. **Taper clonazepam**:
   - Week 1-2: 1 mg/day
   - Week 3-4: 0.75 mg/day (-25%)
   - Week 5-6: 0.5 mg/day
   - Week 7-8: 0.375 mg/day
   - Week 9-10: 0.25 mg/day
   - Week 11-12: 0.125 mg/day
   - Week 13-14: 0.0625 mg/day (or stop)

**Note**: Taper may need to be even slower for long-term users

### Benzodiazepine Overdose

**Clinical Features**:
- **Benzodiazepines alone**:
  - Sedation, drowsiness
  - Ataxia, slurred speech
  - Respiratory depression (mild)
  - **Rarely fatal** (ceiling effect)

- **Benzodiazepines + CNS depressants** (alcohol, opioids):
  - **Severe respiratory depression**
  - **Can be fatal** (synergistic effect)
  - Coma

**Treatment**:

1. **Supportive care**:
   - ABC (airway, breathing, circulation)
   - Mechanical ventilation if needed

2. **Flumazenil** (Romazicon) - benzodiazepine antagonist:
   - **Competitive antagonist** at GABA-A receptor
   - **Reverses benzodiazepine effects**

   **Indications**:
   - Benzodiazepine overdose (severe)
   - Reversal of procedural sedation

   **Dosing**: 0.2 mg IV, repeat q1min (max 3 mg)

   **Cautions**:
   - **Can precipitate seizures** in chronic users (acute withdrawal)
   - **Contraindicated**: Chronic benzodiazepine use, seizure disorder, TCA co-ingestion
   - Short half-life (1 hour) → re-sedation possible (benzodiazepine half-life longer)
   - **Use with extreme caution** - supportive care usually preferred

**Clinical Pearl**: **Flumazenil rarely used** due to seizure risk - supportive care preferred

### Benzodiazepine Drug Interactions

**Pharmacokinetic**:
- **CYP3A4 inhibitors** (ketoconazole, erythromycin, grapefruit juice):
  - ↑Levels of benzodiazepines metabolized by CYP3A4 (alprazolam, midazolam, triazolam)
- **CYP3A4 inducers** (rifampin, carbamazepine, phenytoin):
  - ↓Levels

**Pharmacodynamic**:
- **CNS depressants** (alcohol, opioids, barbiturates, Z-drugs):
  - **Additive respiratory depression** (can be fatal)
  - **Avoid combination** or use with extreme caution
- **Opioids + benzodiazepines**: **Black Box Warning** (FDA)
  - ↑Risk of respiratory depression, coma, death
  - Avoid co-prescription if possible

### Benzodiazepine Use in Specific Conditions

**Alcohol Withdrawal**:
- **First-line treatment**
- **Long-acting preferred** (diazepam, chlordiazepoxide): Smooth taper, less seizure risk
- **Alternative**: Lorazepam (IM/IV, liver disease)
- **Dosing**: Symptom-triggered (CIWA protocol) or fixed-schedule

**Status Epilepticus**:
- **First-line** with phenytoin/fosphenytoin
- **IV lorazepam** (preferred) or **IV diazepam**
- Rapid seizure termination

**Insomnia**:
- **Short-term use only** (<4 weeks)
- **Agents**: Temazepam, triazolam
- **Long-term**: Non-benzodiazepine hypnotics (Z-drugs) or non-pharmacologic (CBT-I)

**Panic Disorder**:
- **Effective** but not first-line (SSRIs preferred long-term)
- **Agents**: Alprazolam, clonazepam
- Risk: Dependence with chronic use

**Generalized Anxiety Disorder**:
- **Short-term use** while waiting for SSRI to work
- **Long-term**: SSRIs/SNRIs preferred (no dependence)

---

## Buspirone

### Mechanism of Action

**Target**: 5-HT1A receptor

**Mechanism**:
- **Partial agonist** at 5-HT1A receptors
  - Presynaptic 5-HT1A (autoreceptors): Agonist → ↓5-HT release (initially)
  - Postsynaptic 5-HT1A: Agonist → anxiolytic effect
- Chronic use → desensitization of presynaptic autoreceptors → net ↑5-HT

**Key Difference from Benzodiazepines**:
- **No GABA activity**
- **No sedation, no dependence, no withdrawal**
- **Delayed onset** (2-4 weeks, like antidepressants)

### Pharmacokinetics

- Oral
- Extensive first-pass metabolism (low bioavailability ~5%)
- Hepatic metabolism (CYP3A4)
- Half-life: 2-3 hours (short)
- TID dosing

### Clinical Uses

1. **Generalized anxiety disorder (GAD)** (FDA-approved)
   - Effective for chronic, persistent worry
2. **Adjunct to SSRIs** for depression, anxiety
3. **Sexual dysfunction** (adjunct - may counteract SSRI effects)

**NOT effective for**:
- Panic disorder
- Social anxiety disorder
- Acute anxiety (slow onset)
- Benzodiazepine withdrawal (no cross-tolerance)

### Advantages

- **No sedation**
- **No dependence or withdrawal**
- **No abuse potential**
- **No psychomotor impairment** (safe to drive)
- **No respiratory depression**
- **Safe in substance abuse history**
- **Safe with alcohol**

### Disadvantages

- **Delayed onset** (2-4 weeks) - not for acute anxiety
- **Less effective than benzodiazepines** for rapid relief
- **Ineffective in patients with prior benzodiazepine use** (no immediate relief)
- Requires TID dosing (short half-life)

### Adverse Effects

**Common**:
- Dizziness, lightheadedness
- Headache
- Nausea
- Nervousness, excitement (paradoxical)

**Generally well-tolerated** - side effects mild

### Dosing

- Start: 7.5 mg BID or 5 mg TID
- Titrate: ↑by 5 mg/day every 2-3 days
- Usual: 20-30 mg/day (divided TID)
- Max: 60 mg/day

### Drug Interactions

- **CYP3A4 inhibitors** (ketoconazole, grapefruit juice): ↑Levels
- **CYP3A4 inducers** (rifampin): ↓Levels
- **MAOIs**: Potential for hypertension (theoretical)

### Clinical Pearls

- **Best for GAD** (chronic worry, not acute panic)
- **Must take regularly** (not PRN) - delayed onset
- **Ineffective for immediate relief** - counsel patients
- **Good alternative for patients with substance abuse history**
- **No benefit in benzodiazepine withdrawal** (no cross-tolerance)
- **May augment SSRIs** for depression, anxiety

---

## Other Anxiolytic Agents

### Hydroxyzine (Vistaril, Atarax)

**Mechanism**: H1 antihistamine (sedating)

**Clinical Uses**:
1. **Generalized anxiety disorder** (short-term)
2. **Pruritus** (itching)
3. **Nausea, vomiting**

**Advantages**:
- **No dependence or withdrawal**
- **No abuse potential**
- Rapid onset (unlike buspirone)

**Adverse Effects**:
- Sedation (common)
- Anticholinergic effects
- QTc prolongation (high doses)

**Dosing**: 25-100 mg QID PRN or scheduled

**Clinical Pearl**: **Good alternative to benzodiazepines** for acute anxiety without abuse potential

### Gabapentin, Pregabalin

**Mechanism**: α2δ subunit of voltage-gated calcium channels

**Clinical Uses**:
1. **Generalized anxiety disorder** (off-label)
2. **Social anxiety disorder** (pregabalin - FDA-approved in Europe)
3. Neuropathic pain
4. Seizures (adjunct)

**Advantages**:
- No dependence (though abuse potential emerging)
- Effective for anxiety (especially with comorbid pain)

**Dosing**:
- Gabapentin: 900-3600 mg/day (divided TID)
- Pregabalin: 150-600 mg/day (divided BID-TID)

### Beta-Blockers (Propranolol)

**Mechanism**: β-adrenergic antagonist → blocks peripheral symptoms of anxiety

**Clinical Uses**:
1. **Performance anxiety** (stage fright) - most common use
2. **Social anxiety disorder** (situational)
3. Akathisia (antipsychotic side effect)

**Effects**:
- Blocks peripheral manifestations: Tremor, tachycardia, sweating
- Does NOT affect cognitive symptoms of anxiety

**Dosing**: 10-40 mg 1 hour before performance

**Clinical Pearl**: **Excellent for performance anxiety** (musicians, public speakers)

### SSRIs/SNRIs

**Role**: **First-line for most anxiety disorders** (long-term treatment)

**Indications**:
- Generalized anxiety disorder (GAD)
- Panic disorder
- Social anxiety disorder
- OCD
- PTSD

**Advantages**:
- No dependence
- Treats comorbid depression
- Long-term efficacy

**Disadvantages**:
- Delayed onset (2-4 weeks)
- May initially worsen anxiety (first 1-2 weeks)

**Strategy**: Often combine with benzodiazepine initially (benzodiazepine tapered once SSRI effective)

---

## Approach to Anxiety Disorders

### First-Line Treatment

**Long-term**:
- **SSRIs/SNRIs** (preferred - no dependence, treat comorbid depression)
- **Buspirone** (GAD only, no dependence)

**Short-term/Adjunct**:
- **Benzodiazepines** (rapid relief while waiting for SSRI to work)
  - Taper after 2-4 weeks when SSRI effective
  - Risk: Some patients unable to discontinue

### Specific Anxiety Disorders

**Generalized Anxiety Disorder (GAD)**:
- First-line: SSRIs, SNRIs, buspirone
- Adjunct: Benzodiazepines (short-term), hydroxyzine

**Panic Disorder**:
- First-line: SSRIs
- Adjunct: Benzodiazepines (alprazolam, clonazepam) - short-term

**Social Anxiety Disorder**:
- First-line: SSRIs, SNRIs
- Situational: Beta-blockers (performance anxiety)
- Alternative: Pregabalin (off-label)

**OCD**:
- First-line: SSRIs (high doses), clomipramine
- Not benzodiazepines

**PTSD**:
- First-line: SSRIs (sertraline, paroxetine)
- Not benzodiazepines (may worsen outcomes)

### When to Use Benzodiazepines

**Appropriate Use**:
- **Acute, severe anxiety** (immediate relief)
- **Short-term adjunct** while starting SSRI (2-4 weeks)
- **Situational anxiety** (PRN use, e.g., flying phobia)
- **Procedure-related anxiety**

**Avoid Long-Term Use**:
- Risk: Dependence, tolerance, withdrawal
- Alternative: SSRIs, buspirone, therapy (CBT)

**Contraindications**:
- **History of substance abuse** (relative)
- Respiratory disease (sleep apnea, COPD)
- Elderly (fall risk)
- Pregnancy

---

## Clinical Pearls

1. **SSRIs first-line for most anxiety disorders** - long-term, no dependence
2. **Benzodiazepines for acute relief** - short-term only, high dependence risk
3. **Buspirone for GAD** - no dependence, but delayed onset (2-4 weeks)
4. **Lorazepam/oxazepam preferred in elderly and liver disease** - no active metabolites
5. **Alprazolam highest abuse potential** - difficult to discontinue
6. **Clonazepam better than alprazolam for panic** - longer duration, less rebound
7. **Never stop benzodiazepines abruptly** - seizure risk, gradual taper required
8. **Flumazenil rarely used** - seizure risk in chronic users
9. **Benzodiazepines + opioids dangerous** - respiratory depression (Black Box Warning)
10. **Hydroxyzine good benzodiazepine alternative** - no dependence, rapid onset
11. **Propranolol for performance anxiety** - blocks peripheral symptoms
12. **Buspirone ineffective for panic or acute anxiety** - only GAD
13. **Avoid benzodiazepines in elderly** (Beers Criteria) - fall risk, cognitive impairment

---

## Key Takeaways

1. **Benzodiazepines**: GABA-A positive allosteric modulators, rapid anxiolytic effect
2. **Effects**: Anxiolytic, sedative, muscle relaxant, anticonvulsant, amnestic
3. **Classification**: Ultra-short (midazolam, triazolam), short-intermediate (alprazolam, lorazepam), long-acting (diazepam, clonazepam)
4. **Lorazepam**: Preferred in elderly/liver disease (no active metabolites, glucuronidation)
5. **Alprazolam**: Highest abuse potential, worst withdrawal, difficult to stop
6. **Adverse effects**: Sedation, cognitive impairment, psychomotor impairment, respiratory depression (with CNS depressants)
7. **Withdrawal**: Can be life-threatening (seizures) - gradual taper required
8. **Overdose**: Flumazenil (caution - seizure risk), supportive care preferred
9. **Buspirone**: 5-HT1A partial agonist, no dependence, delayed onset (2-4 weeks), GAD only
10. **Treatment approach**: SSRIs first-line (long-term), benzodiazepines short-term adjunct
11. **Black Box Warning**: Benzodiazepines + opioids → respiratory depression
12. **Taper**: 10-25% reduction every 1-2 weeks, consider long-acting switch

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. Stahl's Essential Psychopharmacology, 5th Edition
4. Ashton H. Benzodiazepines: How they work and how to withdraw. The Ashton Manual.
5. FDA Drug Safety Communications - Benzodiazepines and Opioids
6. American Psychiatric Association Practice Guidelines for Anxiety Disorders
